SOS1 Inhibitor Compounds Blocking Ras-Family Interaction

The patent employs small molecule inhibitors as intermediary substances that mediate the inhibition of SOS1 activity. These compounds bind to SOS1 and prevent its interaction with Ras-family members, thereby blocking RAS protein activation without directly targeting the Ras proteins themselves. This intermediary approach resolves the contradiction by providing a feasible mechanism to inhibit RAS activation while managing the complexity of targeting the SOS1-Ras interaction pathway.

The patent utilizes parameter changes in the chemical structure of the inhibitors to achieve selective binding to SOS1 and blocking of nucleotide exchange. By modifying molecular parameters such as binding affinity, selectivity, and mechanism of action, the compounds effectively prevent KRas recycling while reducing SOS1 activity. This approach resolves the contradiction by optimizing the parameters of the inhibitor molecules to simultaneously achieve both prevention of recycling and activity reduction.

The patent develops a class of inhibitors with universal applicability across multiple cancer types associated with SOS1-RAS activation. The inhibitors are designed to target the conserved SOS1-Ras interaction mechanism that is common across different cancer types, including Ras-associated, SOS1-associated, and NF1/NF2-associated cancers. This universal design resolves the contradiction by enabling treatment of various cancers through a single mechanism of action while maintaining effective interaction inhibition.